Twist Bioscience Corp
TWST evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TWST—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TWST
Twist Bioscience Corp is a synthetic biology company that manufactures synthetic DNA products for markets including next-generation sequencing (NGS), biopharmaceuticals, and agricultural biotechnology. As of 2026-06-30, the company reported $118.4M in total revenue and a net loss of $35.1M, with $119.6M in cash and equivalents [sec].
Key risk: History of net losses and accumulated deficit
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$8.87B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 clinical trials for Twist Bioscience Corp.
Twist Bioscience Corp is a synthetic biology company that manufactures synthetic DNA products for markets including next-generation sequencing (NGS), biopharmaceuticals, and agricultural biotechnology. As of 2026-06-30, the company reported $118.4M in total revenue and a net loss of $35.1M, with $119.6M in cash and equivalents [sec].
- Twist Bioscience reported total revenue of $118.4M and a net loss of $35.1M for the period ending 2026-06-30 [sec].
- Cash and equivalents stood at $119.6M as of 2026-06-30, with shareholders' equity of $473.0M and total debt of $15.0M [sec].
- The company has an accumulated net deficit of $1,394.1M as of March 31, 2026 [sec_mda · as of 2026-05-04].
- Revenue grew 16.9% year-over-year to $103.7M in the three months ended December 31, 2025, driven by growth in NGS Applications and DNA Synthesis and Protein Solutions [sec_mda · as of 2026-02-02].
- Twist entered an agreement with Invenra Inc. for its B-Body bispecific antibody discovery platform and acquired a 6.24% ownership interest, representing a total commitment of $33.8 million [sec_mda · as of 2026-05-04].
What works
- Revenue growth of 16.9% to $103.7M in Q1 FY2026 (three months ended December 31, 2025) indicates increasing commercial traction [sec_mda · as of 2026-02-02].
- Gross margin improved to 52.0% in the three months ended December 31, 2025, from 48.3% in the prior-year period, reflecting cost efficiencies [sec_mda · as of 2026-02-02].
- The company has a strong intellectual property and platform position in synthetic biology, with applications across NGS, biopharma, and agriculture [sec_mda · as of 2026-05-04].
What to weigh
- Twist has incurred net losses each year since inception, with a net loss of $74.5M for the six months ended March 31, 2026 and an accumulated deficit of $1,394.1M [sec_mda · as of 2026-05-04].
- Cash and equivalents declined to $119.6M as of 2026-06-30 from $171.7M as of March 31, 2026, indicating ongoing cash burn [sec] [sec_mda · as of 2026-05-04].
- The company's ability to achieve profitability depends on the success of existing and new products in synthetic biology and biologic drug industries, which involves significant commercial and regulatory risks [sec_mda · as of 2026-05-04].
From the filings
Quoted directly from source documents.
Twist has an accumulated net deficit of $1,394.1M as of March 31, 2026.
“As of March 31, 2026, we have an accumulated net deficit of $1,394.1 million”
SEC MD&A · May 4, 2026
Revenue grew 16.9% to $103.7M in the three months ended December 31, 2025.
“Revenues growth of 16.9% to $103.7 million from $88.7 million”
SEC MD&A · February 2, 2026
Twist entered an agreement with Invenra Inc. for its B-Body bispecific antibody discovery platform.
“agreement with Invenra Inc. for its proprietary B-Body bispecific antibody discovery platform”
SEC MD&A · May 4, 2026
Gross margin increased to 52.0% in the three months ended December 31, 2025.
“Gross margin increased to 52.0% from 48.3%”
SEC MD&A · February 2, 2026
Risks & what to watch (3)›
Key risks
- History of net losses and accumulated deficit — Twist has incurred net losses each year since inception, with an accumulated deficit of $1,394.1M as of March 31, 2026 [sec_mda · as of 2026-05-04].
- Cash burn and declining cash reserves — Cash and equivalents decreased from $171.7M (March 31, 2026) to $119.6M (June 30, 2026), reflecting ongoing operating losses [sec] [sec_mda · as of 2026-05-04].
- Dependence on commercial success of new products — Profitability depends on success of existing and new products in synthetic biology and biologic drug industries, which carry commercial and regulatory risks [sec_mda · as of 2026-05-04].
What to watch
- Revenue growth trajectory and path to profitability, given recent 16.9% growth but continued net losses [sec_mda · as of 2026-02-02] [sec].
- Cash runway and potential need for additional financing, as cash declined to $119.6M as of 2026-06-30 [sec].
- Progress of the Invenra B-Body bispecific antibody platform collaboration and its contribution to future revenue [sec_mda · as of 2026-05-04].
- Gross margin trends and manufacturing cost improvements at the Wilsonville facility [sec_mda · as of 2026-02-02].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Twist Bioscience Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Twist Bioscience Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.51 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 74 sells (180d)
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
278
Total value held
$3.32B
| Holder | Shares | Value |
|---|---|---|
| ark investment management llc | 6,342,733 | $301.4M |
| blackrock, inc. | 5,554,362 | $263.9M |
| edgepoint investment group inc. | 5,382,521 | $255.8M |
| vanguard capital management llc | 5,278,088 | $250.8M |
| william blair investment management, llc | 5,269,718 | $250.4M |
| state street corp | 3,670,682 | $174.4M |
| vanguard portfolio management llc | 2,649,101 | $125.9M |
| fmr llc | 1,889,945 | $89.8M |
| goldman sachs group inc | 1,705,546 | $81.0M |
| geode capital management, llc | 1,519,713 | $72.2M |
Showing top 10 of 278 institutional holders of Twist Bioscience Corp. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 28.7%
- Days to cover
- 11.0
- Shares short
- 13,914,949
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TWST short interestGovernance
Frequently asked questions
What is the AI investment thesis for Twist Bioscience Corp?
Twist Bioscience Corp is a synthetic biology company that manufactures synthetic DNA products for markets including next-generation sequencing (NGS), biopharmaceuticals, and agricultural biotechnology. As of 2026-06-30, the company reported $118.4M in total revenue and a net loss of $35.1M, with $119.6M in cash and equivalents [sec].
Who is the CEO of Twist Bioscience Corp?
Dr. Emily Marine Leproust Ph.D. is the chief executive officer of Twist Bioscience Corp (TWST).
Where is Twist Bioscience Corp headquartered?
Twist Bioscience Corp (TWST) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does Twist Bioscience Corp focus on?
Twist Bioscience Corp develops therapies across Oncology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.